drug
budesonide DR
Marketedupdated 5mo agoby Calliditas Therapeutics AB
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval8 co-mentions · 4 sources
- drugbudesonide ER6 co-mentions · 6 sources
- drugBUDESONIDE6 co-mentions · 6 sources
- drugPulmicort6 co-mentions · 6 sources
- drugPulmicort Turbohaler6 co-mentions · 6 sources
- tagSmall Molecule4 co-mentions · 4 sources
- tagRecall2 co-mentions · 2 sources
- companyAstraZeneca Pharmaceuticals LP1 co-mentions · 1 sources
all catalysts(4)
Trials studying budesonide DR
- phase4Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
- phase3A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
- phase1Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
- phase3Budesonide/Formoterol Inhalation Powder in Adults With Asthma
- phase4A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
- phase3A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- phase3Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
- phase4Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 9, 2026
41 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (35)
- Jan 23, 2043method-of-use (U-3810)US 11896719
- Jan 23, 2043method-of-use (U-4086)US 12171882
- Jan 23, 2043formulationUS 12171883
- Jan 23, 2043formulationUS 12311057
- Jan 10, 2039formulationUS 11260064
- Jan 10, 2039method-of-use (U-3820)US 11564934
- Oct 5, 2038formulationUS 11331442
- Oct 5, 2038formulationUS 11833292
- Sep 9, 2036method-of-use (U-2554)US 10172802
- Sep 9, 2036method-of-use (U-2554)US 10172802
- Sep 9, 2036formulationUS 9707182
- Sep 9, 2036formulationUS 9707182
- Sep 7, 2031formulationUS 103073754.9y
- Sep 7, 2031formulationUS 106608584.9y
- Sep 7, 2031formulationUS 88950644.9y
- Sep 7, 2031formulationUS 91320934.9y
- Sep 7, 2031formulationUS 91925814.9y
- Mar 17, 2031method-of-use (U-2889)US 88152584.5y
- May 28, 2030formulationUS 107167533.7y
- May 28, 2030method-of-use (U-2889)US 83242663.7y
- May 28, 2030method-of-use (U-2889)US 87038063.7y
- May 28, 2030formulationUS 88087133.7y
- May 28, 2030method-of-use (U-2889)US 94150093.7y
- May 28, 2030formulationUS 94631613.7y
- Aug 3, 2029method-of-use (U-3820)US 83241922.8y
- Aug 1, 2029formulationUS 90503682.8y
- May 7, 2029formulationUS 84919322.6y
- Nov 22, 2028formulationUS 102930522.2y
- Nov 12, 2028method-of-use (U-3820)US 113578592.1y
- Nov 9, 2026formulationUS 1119782241d
- Nov 9, 2026formulationUS 1141329641d
- Nov 9, 2026method-of-use (U-3820)US 849725841d
- Nov 9, 2026formulationUS 867954541d
- Nov 9, 2026method-of-use (U-3820)US 897524341d
- Nov 9, 2026method-of-use (U-3820)US 911986341d
FDA exclusivities (4)
- Feb 9, 2031ODE-466Orphan Drug (7y)4.4y
- Dec 20, 2030ODE-464Orphan Drug (7y)4.2y
- Dec 15, 2028ODE-389Orphan Drug (7y)2.2y
- Feb 9, 2027NPNP133d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that